COMMUNIQUÉS West-GlobeNewswire

-
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
11/12/2017 -
Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
11/12/2017 -
Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation
11/12/2017 -
SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox
11/12/2017 -
Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysis
11/12/2017 -
Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma
11/12/2017 -
Insider tradings
11/12/2017 -
Proposal of candidates to the Board of Directors
11/12/2017 -
REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED
11/12/2017 -
Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting
11/12/2017 -
Galapagos to enter NASDAQ Biotech Index
11/12/2017 -
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting
11/12/2017 -
Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
11/12/2017 -
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
11/12/2017 -
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency
11/12/2017 -
ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting
10/12/2017 -
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
10/12/2017 -
Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting
10/12/2017 -
Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
10/12/2017
Pages